Your browser doesn't support javascript.
loading
ATP13A2 (PARK9) and basal ganglia function.
Croucher, Kristina M; Fleming, Sheila M.
Affiliation
  • Croucher KM; Department of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, OH, United States.
  • Fleming SM; Biomedical Sciences Graduate Program, Kent State University, Kent, OH, United States.
Front Neurol ; 14: 1252400, 2023.
Article de En | MEDLINE | ID: mdl-38249738
ABSTRACT
ATP13A2 is a lysosomal protein involved in polyamine transport with loss of function mutations associated with multiple neurodegenerative conditions. These include early onset Parkinson's disease, Kufor-Rakeb Syndrome, neuronal ceroid lipofuscinosis, hereditary spastic paraplegia, and amyotrophic lateral sclerosis. While ATP13A2 mutations may result in clinical heterogeneity, the basal ganglia appear to be impacted in the majority of cases. The basal ganglia is particularly vulnerable to environmental exposures such as heavy metals, pesticides, and industrial agents which are also established risk factors for many neurodegenerative conditions. Not surprisingly then, impaired function of ATP13A2 has been linked to heavy metal toxicity including manganese, iron, and zinc. This review discusses the role of ATP13A2 in basal ganglia function and dysfunction, potential common pathological mechanisms in ATP13A2-related disorders, and how gene x environment interactions may contribute to basal ganglia dysfunction.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Risk_factors_studies Langue: En Journal: Front Neurol Année: 2023 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Suisse

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Risk_factors_studies Langue: En Journal: Front Neurol Année: 2023 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Suisse